bhc-20220928

0000885590-22-000054.txt : 20220928 0000885590-22-000054.hdr.sgml : 20220928 20220928090551 ACCESSION NUMBER: 0000885590-22-000054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220928 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220928 DATE AS OF CHANGE: 20220928 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 221272886 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 bhc-20220928.htm 8-K bhc-20220928

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

September 28, 2022

Date of report (Date of the earliest event reported)

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

British Columbia

Canada

001-14956

98-0448205

(State or Other Jurisdiction of Incorporation or Organization)

(Commission File Number)

(I.R.S. Employer Identification Number)

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, No Par Value	BHC	New York Stock Exchange	Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On September 28, 2022, Bausch Health Companies Inc. (the “Company”) announced the final results and expiration, as of 11:59 p.m., New York City time, on September 27, 2022, of its previously announced (i) offers to exchange (the “Exchange Offers”) (A) the Company’s outstanding 5.25% Senior Notes due 2031, 5.25% Senior Notes due 2030, 5.00% Senior Notes due 2029, 6.25% Senior Notes due 2029, 7.25% Senior Notes due 2029, 5.00% Senior Notes due 2028, 7.00% Senior Notes due 2028, 9.00% Senior Notes due 2025 and (B) Bausch Health Americas, Inc.’s (“BHA”) outstanding 9.25% Senior Notes due 2026 and 8.50% Senior Notes due 2027 (collectively, the “Existing Notes”) for up to an aggregate principal amount of $4.0 billion of new secured notes, comprised of (1) up to $2.5 billion in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 and up to $500.0 million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030, in each case, to be issued by the Company and (2) $1.0 billion in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 to be issued by 1375209 B.C. Ltd., an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation, and (ii) solicitations of consent by the Company and BHA from holders of Existing Notes to amend certain provisions of the applicable indenture governing the related series of Existing Notes (the “Consent Solicitations” and, together with the Exchange Offers, the “Offers”).

A copy of the Company’s press release announcing the results of the Offers is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



99.1						Press release issued by the Company on September 28, 2022.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 28, 2022


			BAUSCH HEALTH COMPANIES INC.


By:			/s/ Tom Vadaketh
			Name: Tom Vadaketh
			Title: Executive Vice President, Chief Financial Officer

EX-99.1 2 ex991-bhcannouncesfinalres.htm EX-99.1 Document

Investor Contact: Media Contacts:

Christina Cheng Kevin Wiggins

ir@bauschhealth.com corporate.communications@bauschhealth.com

(514) 856-3855 (848) 541-3785

(877) 281-6642 (toll free)

Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

LAVAL, Quebec – Sept. 28, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (the “Company”) announced today the final results and expiration of its previously announced offers (the “Exchange Offers”) to exchange the existing senior notes set forth in the table below (the “Existing Senior Notes”) for up to an aggregate principal amount of $4.0 billion (the “Maximum New Secured Notes Amount”) of New Secured Notes (as defined below) and the related solicitations of consents (the “Consent Solicitations” and, together with the Exchange Offers, the “Offers”) to amend certain provisions of the indentures (the “Proposed Amendments”) with respect to the respective applicable series of Existing Senior Notes. The terms and conditions of the offers and consent solicitations are described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated August 30, 2022 (the “Exchange Offer Memorandum”).

The Exchange Offers expired at 11:59 p.m., New York City time, on September 27, 2022 (the “Expiration Time”). As reported by D.F. King & Co., Inc., the exchange agent and information agent for the Offers, as of the Expiration Time, an aggregate principal amount of $5,594,432,000 of Existing Senior Notes had been validly tendered (and not validly withdrawn) in the Offers, as set forth in the table below.


Title of Existing Senior Notes	CUSIP Number(1) (Rule 144A/Reg S)	Principal Amount Outstanding	Tender Cap	Acceptance Priority Level(2)	Principal Amount Tendered
9.00% Senior Notes due 2025	91911KAP7 / C94143AM3	$ 1,500,000,000	N/A	1	$ 540,662,000
9.25% Senior Notes due 2026(3)	91911XAV6 / U9098VAN2	$ 1,500,000,000	N/A	2	$ 752,398,000
8.50% Senior Notes due 2027(3)	91911XAW4 / U9098VAP7	$ 1,750,000,000	$500,000,000(4)	3	$ 500,000,000
5.25% Senior Notes due 2031	071734AL1 / C07885AG8	$ 909,188,000	N/A	4	$ 336,499,000
5.25% Senior Notes due 2030	071734AJ6 / C07885AE3	$ 1,201,000,000	N/A	5	$ 331,952,000
5.00% Senior Notes due 2029	071734AM9 / C07885AH6	$ 834,000,000	N/A	6	$ 371,067,000
5.00% Senior Notes due 2028	071734AH0 / C07885AD5	$ 1,176,000,000	N/A	7	$ 710,075,000
6.25% Senior Notes due 2029	071734AK3 / C07885AF0	$ 1,406,000,000	N/A	8	$ 540,099,000
7.25% Senior Notes due 2029	071734AF4 / C07885AC7	$ 745,000,000	N/A	9	$ 372,967,000
7.00% Senior Notes due 2028	071734AD9 / C07885AB9	$ 748,000,000	N/A	10	$ 539,614,000
8.50% Senior Notes due 2027(3)	91911XAW4 / U9098VAP7	$ 1,750,000,000	N/A	11	$ 599,099,000

(1)No representation is made as to the correctness or accuracy of the CUSIP numbers listed in this press release or printed on the Existing Senior Notes. They are provided solely for convenience.

(2)Existing Senior Notes accepted for exchange on the settlement date will be accepted in accordance with their Acceptance Priority Levels set forth herein (with “1” being the highest Acceptance Priority Level and “11” being the lowest Acceptance Priority Level). The Offerors will only accept for exchange Existing Senior Notes up to an aggregate principal amount that will not cause the aggregate principal amount of New Secured Notes issued pursuant to the Offers to exceed the Maximum New Secured Notes Amount.

(3)Bausch Health Americas, Inc. (“BHA”) is the issuer and the Company is a guarantor of such series of Existing Senior Notes.

(4)No more than $500.0 million aggregate principal amount of the 8.50% Senior Notes due 2027 (the “Level 3 Tender Cap”) will be purchased at level “3” in the Exchange Offers.

Subject to the terms and conditions set forth in the Exchange Offer Memorandum, upon settlement of the Exchange Offers, which is currently expected to occur on September 30, 2022 (the “Settlement Date”), there will be approximately $3,125 million of New Secured Notes issued in the Offers, consisting of approximately (i) $1,774 million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the “New First Lien Notes”), (ii) $352 million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the “New Second Lien Notes” and, together with the New First Lien Notes, the “New BHC Secured Notes”), in each case, to be issued by the Company, and (iii) $999 million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the “Intermediate Holdco Secured Notes” and, together with the New BHC Secured Notes, the “New Secured Notes”) to be issued by 1375209 B.C. Ltd. (the “Holdco Issuer” and, together with the Company, the “Offerors”), an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. All Eligible Holders (as defined in the Exchange Offer Memorandum) of Existing Senior Notes accepted for exchange pursuant to the Offers on the Settlement Date will also be paid a cash amount equal to accrued and unpaid interest for such series of Existing Senior Notes from the last interest payment date for such series of Existing Senior Notes to, but not including, the Settlement Date.

In addition to the previously announced receipt of the requisite number of consents to adopt the Proposed Amendments with respect to the (i) 9.25% Senior Notes due 2026, (ii) 8.50% Senior Notes due 2027, (iii) 5.00% Senior Notes due 2028 and (iv) 7.00% Senior Notes due 2028 and the execution of the supplemental indentures related thereto, as of the Expiration Time, the Company also received the requisite number of consents to adopt the Proposed Amendments with respect to the 7.25% Senior Notes due 2029. Accordingly, pursuant to the terms set forth in the Exchange Offer Memorandum, the Company intends to enter into a supplemental indenture with the trustee for the 7.25% Senior Notes due 2029 to effectuate the applicable Proposed Amendments. Each supplemental indenture will become operative upon the settlement date of the Offers.

The New Secured Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The New Secured Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any issuance of New Secured Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the New Secured Notes in the United States and shall not constitute an offer, solicitation or sale of the New Secured Notes in any jurisdiction where such offering or sale would be unlawful. There shall not be any sale of the New Secured Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Bausch Health Companies Inc.

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our approximately 88.7% ownership of Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-Looking Statements

This news release may contain forward-looking statements about the future performance of the Company, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Company’s overall business, including those more fully described in the Company’s most recent annual report on Form 10-K and detailed from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission and the Canadian securities administrators, which factors are incorporated herein by reference.

###

EX-101.SCH 3 bhc-20220928.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bhc-20220928_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 bhc-20220928_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Document	Sep. 28, 2022
Cover [Abstract]
Document Type	8-K
Document Period End Date	Sep. 28, 2022
Entity Registrant Name	Bausch Health Companies Inc.
Entity Incorporation, State or Country Code	A1
Entity Address, Country	CA
Entity File Number	001-14956
Entity Tax Identification Number	98-0448205
Entity Address, Address Line One	2150 St. Elzéar Blvd. West
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H7L 4A8
City Area Code	514
Local Phone Number	744-6792
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, No Par Value
Trading Symbol	BHC
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Central Index Key	0000885590
Amendment Flag	false

XML 7 bhc-20220928_htm.xml IDEA: XBRL DOCUMENT 0000885590 2022-09-28 2022-09-28 0000885590 false 8-K 2022-09-28 Bausch Health Companies Inc. A1 CA 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document Sheet http://www.bauschhealth.com/role/Document Document Cover 1 false false All Reports Book All Reports bhc-20220928.htm bhc-20220928.xsd bhc-20220928_lab.xml bhc-20220928_pre.xml ex991-bhcannouncesfinalres.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bhc-20220928.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "bhc-20220928.htm" ] }, "labelLink": { "local": [ "bhc-20220928_lab.xml" ] }, "presentationLink": { "local": [ "bhc-20220928_pre.xml" ] }, "schema": { "local": [ "bhc-20220928.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20220928", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20220928.htm", "contextRef": "ib3c32ea6a97342afaf6b66b7e7010d42_D20220928-20220928", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document", "role": "http://www.bauschhealth.com/role/Document", "shortName": "Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20220928.htm", "contextRef": "ib3c32ea6a97342afaf6b66b7e7010d42_D20220928-20220928", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bauschhealth.com/role/Document" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000885590-22-000054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885590-22-000054-xbrl.zip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